Nykode Therapeutics and MSD Expand Collaboration for Phase 2 Trial of VB10.16 Cancer Vaccine

Nykode Therapeutics expands collaboration with MSD to conduct a phase 2 trial of VB10.16 with KEYTRUDA in HPV16-positive cervical cancer patients. The trial aims to improve treatment outcomes for locally advanced cervical cancer, a disease with high mortality rates.

author-image
Trim Correspondents
New Update
Nykode Therapeutics and MSD Expand Collaboration for Phase 2 Trial of VB10.16 Cancer Vaccine

Nykode Therapeutics and MSD Expand Collaboration for Phase 2 Trial of VB10.16 Cancer Vaccine

Norway-based Nykode Therapeutics ASA has expanded its collaboration with MSD (Merck & Co., Inc.) to conduct a phase 2 trial evaluating Nykode's lead candidate, VB10.16, in Combination with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in HPV16-positive patients with locally advanced cervical cancer undergoing chemoradiotherapy.

VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The phase 2 trial will enroll HPV16-positive high-risk patients with locally advanced cervical cancer. Nykode has reported promising data from the phase 2 VB C-02 trial, with a median overall survival not yet reached (estimated to 25 months at the time of analysis).

Why this matters: This collaboration has the potential to improve treatment outcomes for patients with locally advanced cervical cancer, a disease with high mortality rates and limited treatment options. The development of innovative cancer immunotherapies like VB10.16 could also pave the way for new approaches to treating other types of cancer.

The VB10.16 Clinical Development program is expanding into new indications, including head and neck cancer. Agnete Fredriksen, EVP, Chief Scientific Officer and Business Development at Nykode Therapeutics, expressed excitement about the collaboration: "We are excited to expand our clinical development to include earlier stages of cervical cancer where there is a significant unmet medical need, and we see a huge potential for cancer vaccines. We are thrilled to continue building on our already established, highly valued collaboration with the experienced and talented team at MSD, a global leader in immuno-oncology."

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. The company's modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong, and long-lasting antigen-specific immune response in cancer.

The expanded Collaboration between Nykode Therapeutics and MSD represents a significant step forward in developing innovative cancer immunotherapies. By combining VB10.16 with KEYTRUDA, the phase 2 trial aims to address the unmet medical need in locally advanced cervical cancer and explore the potential of therapeutic cancer vaccines in improving patient outcomes.

Key Takeaways

  • Nykode Therapeutics expands collaboration with MSD to conduct phase 2 trial of VB10.16 with KEYTRUDA.
  • VB10.16 is a therapeutic cancer vaccine for HPV16-induced malignancies, with promising phase 2 data.
  • Trial will enroll HPV16-positive patients with locally advanced cervical cancer undergoing chemoradiotherapy.
  • Collaboration aims to improve treatment outcomes for patients with limited options and high mortality rates.
  • Nykode Therapeutics is expanding VB10.16 development into head and neck cancer and other indications.